HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
26 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
KRT5
keratin 5
Chromosome 12 Β· 12q13.13
NCBI Gene: 3852Ensembl: ENSG00000186081.12HGNC: HGNC:6442UniProt: P13647
320PubMed Papers
27Diseases
0Drugs
95Pathogenic Variants
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
membraneextracellular exosomeprotein-containing complexscaffold protein bindingepidermolysis bullosa simplex 2C, localizedepidermolysis bullosa simplex 2B, generalized intermediateepidermolysis bullosa simplex 2A, generalized severeDowling-Degos disease 1
✦AI Summary

KRT5 encodes keratin 5, a type II intermediate filament protein essential for maintaining structural integrity and barrier function in basal epithelial cells. KRT5 forms heterodimeric complexes with KRT14 in basal keratinocytes, providing cytoskeletal support and mechanical resilience 1. In lung pathology, KRT5+ basal cells emerge aberrantly in distal alveolar regions during fibrotic diseases like idiopathic pulmonary fibrosis (IPF), where they represent a pathologic epithelial population contributing to tissue remodeling 23. Human alveolar type 2 cells can transdifferentiate into KRT5+ basal cells through a TGF-Ξ²1-mediated pathway involving sFRP2 and noncanonical Wnt signaling 4. KRT5+ distal airway stem cells demonstrate regenerative capacity, being essential for lung repair following injury and capable of differentiating into multiple epithelial cell types including pneumocytes 56. The extracellular matrix composition, particularly SPARC protein levels, modulates KRT5+ cell migration and remodeling gene expression in fibrotic conditions 7. In melanoma, KRT5 functions as a tumor suppressor, with reduced expression promoting cell proliferation, migration, and invasion, suggesting its protective role against metastasis 8.

Sources cited
1
KRT5 forms heterodimeric complexes with KRT14 in basal keratinocytes and is involved in wound repair and inflammatory responses
PMID: 31374826
2
KRT5+ pathologic epithelial cell populations are highly enriched in pulmonary fibrosis lungs
PMID: 32832598
3
Human alveolar type 2 cells transdifferentiate into KRT5+ basal cells in response to fibrotic signaling
PMID: 34969962
4
TGF-Ξ²1/sFRP2 noncanonical Wnt signaling axis promotes KRT5+ basal cell program in IPF
PMID: 38980870
5
KRT5+ distal airway stem cells are essential for lung regeneration and can differentiate into pneumocytes
PMID: 25383540
6
KRT5+ basal cells in organoids can form lumens with differentiated club and ciliated cells
PMID: 33238290
7
Extracellular matrix composition, particularly SPARC, modulates KRT5+ cell migration and gene expression
PMID: 37758700
8
KRT5 knockdown promotes melanoma cell proliferation, migration, and invasion, suggesting tumor suppressor function
PMID: 35054979
Disease Associationsβ“˜27
epidermolysis bullosa simplex 2C, localizedOpen Targets
0.77Strong
epidermolysis bullosa simplex 2B, generalized intermediateOpen Targets
0.76Strong
epidermolysis bullosa simplex 2A, generalized severeOpen Targets
0.76Strong
Dowling-Degos disease 1Open Targets
0.71Strong
Epidermolysis bullosa simplex with mottled pigmentationOpen Targets
0.70Strong
Epidermolysis bullosa simplex, Dowling-Meara typeOpen Targets
0.69Moderate
Localized epidermolysis bullosa simplexOpen Targets
0.69Moderate
epidermolysis bullosa simplex 2F, with mottled pigmentationOpen Targets
0.67Moderate
epidermolysis bullosa simplex 2d, generalized, intermediate or severe, autosomal recessiveOpen Targets
0.66Moderate
Generalized epidermolysis bullosa simplex, non-Dowling-Meara typeOpen Targets
0.66Moderate
epidermolysis bullosa simplex 1C, localizedOpen Targets
0.65Moderate
Epidermolysis bullosa simplex with circinate migratory erythemaOpen Targets
0.65Moderate
epidermolysis bullosa simplexOpen Targets
0.65Moderate
epidermolysis bullosa simplex 1A, generalized severeOpen Targets
0.63Moderate
Dowling-Degos diseaseOpen Targets
0.60Moderate
basal cell carcinomaOpen Targets
0.57Moderate
skin neoplasmOpen Targets
0.55Moderate
skin cancerOpen Targets
0.55Moderate
epidermolysis bullosa simplex 1B, generalized intermediateOpen Targets
0.53Moderate
epidermolysis bullosa simplex 2E, with migratory circinate erythemaOpen Targets
0.50Moderate
Dowling-Degos disease 1UniProt
Epidermolysis bullosa simplex 2A, generalized severeUniProt
Epidermolysis bullosa simplex 2B, generalized intermediateUniProt
Epidermolysis bullosa simplex 2C, localizedUniProt
Epidermolysis bullosa simplex 2D, generalized, intermediate or severe, autosomal recessiveUniProt
Epidermolysis bullosa simplex 2E, with migratory circinate erythemaUniProt
Epidermolysis bullosa simplex 2F, with mottled pigmentationUniProt
Pathogenic Variants95
NM_000424.4(KRT5):c.579C>A (p.Asn193Lys)Pathogenic
not provided|Epidermolysis bullosa simplex 1A, generalized severe
β˜…β˜…β˜†β˜†2026β†’ Residue 193
NM_000424.4(KRT5):c.1429G>A (p.Glu477Lys)Pathogenic
Epidermolysis bullosa simplex 1A, generalized severe|not provided|Epidermolysis bullosa simplex 1C, localized|Epidermolysis bullosa simplex with mottled pigmentation|Epidermolysis bullosa simplex|Epidermolysis bullosa simplex 2A, generalized severe|KRT5-related disorder|Epidermolysis bullosa simplex 2B, generalized intermediate
β˜…β˜…β˜†β˜†2026β†’ Residue 477
NM_000424.4(KRT5):c.980T>C (p.Met327Thr)Pathogenic
not provided|7 conditions|Epidermolysis bullosa simplex, Koebner type|Epidermolysis bullosa simplex 2C, localized|KRT5-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 327
NM_000424.4(KRT5):c.482T>G (p.Ile161Ser)Pathogenic
not provided|Epidermolysis bullosa simplex 2C, localized|Epidermolysis bullosa simplex 1C, localized|KRT5-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 161
NM_000424.4(KRT5):c.74C>T (p.Pro25Leu)Pathogenic
Epidermolysis bullosa simplex with mottled pigmentation|not provided|Epidermolysis bullosa simplex|KRT5-related disorder|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 25
NM_000424.4(KRT5):c.502G>A (p.Glu168Lys)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 168
NM_000424.4(KRT5):c.556G>A (p.Val186Met)Pathogenic
not provided|Epidermolysis bullosa simplex
β˜…β˜…β˜†β˜†2025β†’ Residue 186
NM_000424.4(KRT5):c.1649del (p.Gly550fs)Pathogenic
Epidermolysis bullosa simplex with migratory circinate erythema|not provided|Epidermolysis bullosa simplex|Epidermolysis bullosa simplex with mottled pigmentation|KRT5-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 550
NM_000424.4(KRT5):c.1388T>C (p.Leu463Pro)Pathogenic
not provided|Epidermolysis bullosa simplex|Epidermolysis bullosa simplex 2B, generalized intermediate
β˜…β˜…β˜†β˜†2024β†’ Residue 463
NM_000424.4(KRT5):c.968T>C (p.Val323Ala)Pathogenic
not provided|Epidermolysis bullosa simplex|Epidermolysis bullosa simplex 2B, generalized intermediate
β˜…β˜…β˜†β˜†2024β†’ Residue 323
NM_000424.4(KRT5):c.991C>T (p.Arg331Cys)Pathogenic
not provided|Epidermolysis bullosa simplex 1C, localized|Dowling-Degos disease 1
β˜…β˜…β˜†β˜†2024β†’ Residue 331
NM_000424.4(KRT5):c.992G>A (p.Arg331His)Pathogenic
not provided|KRT5-related disorder|Epidermolysis bullosa
β˜…β˜…β˜†β˜†2024β†’ Residue 331
NM_000424.4(KRT5):c.1396G>C (p.Glu466Gln)Pathogenic
Epidermolysis bullosa simplex|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 466
NM_000424.4(KRT5):c.527A>G (p.Asn176Ser)Pathogenic
not provided|Epidermolysis bullosa simplex with mottled pigmentation
β˜…β˜…β˜†β˜†2024β†’ Residue 176
NM_000424.4(KRT5):c.495G>C (p.Arg165Ser)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 165
NM_000424.4(KRT5):c.1283C>T (p.Ala428Val)Pathogenic
not provided|Epidermolysis bullosa simplex
β˜…β˜…β˜†β˜†2023β†’ Residue 428
NM_000424.4(KRT5):c.1400T>C (p.Ile467Thr)Pathogenic
not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 467
NM_000424.4(KRT5):c.508G>A (p.Glu170Lys)Pathogenic
not provided|Epidermolysis bullosa simplex|Epidermolysis bullosa simplex 2C, localized|KRT5-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 170
NM_000424.4(KRT5):c.1427G>A (p.Gly476Asp)Pathogenic
not provided|Epidermolysis bullosa simplex 1A, generalized severe|Epidermolysis bullosa simplex 2B, generalized intermediate
β˜…β˜…β˜†β˜†2023β†’ Residue 476
NM_000424.4(KRT5):c.1398G>C (p.Glu466Asp)Pathogenic
Epidermolysis bullosa simplex|not provided
β˜…β˜…β˜†β˜†2022β†’ Residue 466
View on ClinVar β†—
Related Genes
COL17A1Protein interaction100%FLGProtein interaction100%KRT3Protein interaction100%LORICRINProtein interaction100%KRT1Protein interaction92%KRT2Protein interaction87%
Tissue Expression6 tissues
Bone Marrow
100%
Liver
78%
Lung
57%
Ovary
44%
Brain
18%
Heart
10%
Gene Interaction Network
Click a node to explore
KRT5COL17A1FLGKRT3LORICRINKRT1KRT2
PROTEIN STRUCTURE
Preparing viewer…
PDB6JFV Β· 2.60 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.54Moderately Constrained
pLIβ“˜
0.90Intolerant
Observed/Expected LoF0.35 [0.24–0.54]
RankingsWhere KRT5 stands among ~20K protein-coding genes
  • #1,043of 20,598
    Most Researched320 Β· top 10%
  • #807of 5,498
    Most Pathogenic Variants95 Β· top quartile
  • #3,387of 17,882
    Most Constrained (LOEUF)0.54 Β· top quartile
Genes detectedKRT5
Sources retrieved26 papers
Response timeβ€”
πŸ“„ Sources
26β–Ό
1
Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis.
PMID: 32832598
Sci Adv Β· 2020
1.00
2
Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5
PMID: 34969962
Nat Cell Biol Β· 2022
0.90
3
A fibroblast-dependent TGF-Ξ²1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis.
PMID: 38980870
J Clin Invest Β· 2024
0.80
4
Lung extracellular matrix modulates KRT5
PMID: 37758700
Nat Commun Β· 2023
0.70
5
Viral infection induces inflammatory signals that coordinate YAP regulation of dysplastic cells in lung alveoli.
PMID: 39352385
J Clin Invest Β· 2024
0.64